How GHRH binds its receptor on pituitary somatotrophs, triggers GH release, and controls the GH/IGF-1 endocrine axis through feedback regulation.
Analysis & Testing · August 6, 2026When independent lab testing builds trust: USP reference standards, multi-lab validation, and regulatory acceptance in peptide quality assurance.
Lab Technique · August 6, 2026How pH affects degradation: asparagine deamidation, methionine oxidation, and buffer strategies to preserve peptide integrity during storage.
Research & Study · August 6, 2026Clinical trial testing topical GHK-Cu for accelerating skin wound healing. Preclinical evidence and trial design explained.
Research Methodology · August 6, 2026P-values depend on sample size. Learn effect size, why statistical significance doesn't measure practical importance, and how to read research critically.
Comparison · August 6, 2026GHRH analog vs ghrelin-mimetic: mechanisms, half-life, IGF-1 effects, and why researchers study them together in endocrinology.
Mechanism Deep-Dive · August 6, 2026How thymosin beta-4 binds G-actin, promotes cell migration, and accelerates angiogenesis in preclinical wound healing models.
Regulatory · August 6, 2026FDA labeling rules for research peptides: 21 CFR 801, quality system regulations, and what research-use-only disclaimers must include.
Analysis & Testing · August 6, 2026AAA explained: why it's the reference method for peptide quantification, hydrolysis, derivatization, and comparison to other assays.
Lab Technique · August 6, 2026Master peptide solubility: understand isoelectric point, hydrophobic vs hydrophilic residues, pH optimization, and solvent strategies.
Regulatory · August 5, 2026Research peptides are banned in sport. The 2026 WADA list classifies BPC-157, TB-500, CJC-1295, ipamorelin and others as prohibited (S0-S4). Research vs. sport use explained.
Quality & Analysis · August 5, 2026Bacterial endotoxins (LPS) contaminate peptides and trigger false inflammatory signals in cell culture. LAL assay detects and quantifies—acceptable limits for research explained.
Lab Technique · August 5, 2026Freeze-drying removes water that drives hydrolysis, oxidation, and microbial growth. Extends shelf life from weeks in solution to 1–5 years as lyophilized powder. Process explained.
Study Summary · August 5, 202680 peer-reviewed studies reviewed through March 2026. Actin regulation, 42–61% faster wound closure in animal models, Phase 2 human trials ongoing. Safety questions remain.
Research Methodology · August 5, 2026Every experiment needs controls to prove the protocol works and noise is minimal. Design rules for positive (known result) and negative (background) controls in peptide assays.
Research Comparison · August 5, 2026Semax: BDNF + dopamine (cognitive activation). Selank: GABA + serotonin (anxiety reduction). Complementary mechanisms; often combined. Russian nootropic research peptides compared.
Mechanism Deep-Dive · August 5, 2026Cardiolipin is rare, essential inner-membrane lipid. SS-31 (elamipretide) targets it to stabilize ATP production and prevent ischemia-reperfusion damage in preclinical models.
Regulatory & Compliance · August 5, 2026DEA List I/II chemical registration, CBP clearance, customs broker guidance, and state-level restrictions. When registration is needed for peptide import into the USA.
Quality & Analysis · August 5, 2026Residual water in lyophilized peptides accelerates degradation and affects concentration calculations. Karl Fischer titration measures moisture (1–5% typical). Reading your COA water data.
Lab Technique · August 5, 2026Each freeze-thaw reduces activity 20–50% through aggregation, oxidation, hydrolysis. Aliquoting before the first freeze preserves 80–90% vs 50–70% loss from repeated thawing.
Regulatory · August 4, 2026Research chemicals are legal nationwide, but 14+ states have additional restrictions. State-level compliance and the 2026 regulatory landscape.
Quality & Analysis · August 4, 2026Trifluoroacetic acid can comprise 10–45% of peptide mass and cause unexpected cytotoxicity in cell assays. Detection and exchange solutions.
Lab Technique · August 4, 2026Divide reconstituted peptides into single-use aliquots before any freezing. Preserve 80–90% of activity vs 50–70% loss from repeated thawing.
Study Summary · August 4, 2026Organ toxicology, endocrine effects, and the critical safety questions that remain unanswered in human research.
Research Methodology · August 4, 2026Evaluating study design, statistical rigor, conflict of interest, and spotting red flags in peptide research.
Research Comparison · August 4, 2026Two GH secretagogues working through separate pathways. Why combining them produces synergistic GH/IGF-1 effects.
Mechanism Deep-Dive · August 4, 2026Telomere length, replicative senescence, and what 2025–2026 cell-culture research shows about telomerase activation.
Regulatory · August 4, 2026The billion-dollar barrier between research compound and approved drug. NDA/BLA costs, clinical-trial phase failures, and the 503A alternative.
Quality Analysis · August 4, 2026HPLC purity ≠ net peptide content. A 99% pure sample may contain only 70% actual peptide by weight.
Lab Technique · August 4, 2026Each freeze-thaw cycle reduces peptide activity by 20–50%. Aggregation, oxidation, hydrolysis mechanisms and best-practice aliquoting.
Industry Overview · August 3, 2026The metabolic peptide race (semaglutide → tirzepatide → retatrutide), the FDA's July 2026 compounding advisory decisions, and what a regulated pathway means for research peptides in 2026.
Research Methodology · August 3, 2026Why animal models fail to predict human outcomes, translational failure rates, and how to read preclinical peptide research critically.
Regulatory · August 3, 2026How 503A pharmacies and 503B outsourcing facilities differ, why peptides are handled specially, and the 2026 regulatory shift.
Quality & Analysis · August 3, 2026How MS confirms peptide identity by monoisotopic mass, what a complete COA should include, and why both MS and HPLC matter.
Lab Technique · August 3, 2026-20°C vs -80°C, humidity threats, reconstituted-peptide timelines, and freeze-thaw cycle limits based on 2025–2026 stability research.
Research Explainer · August 3, 2026What the Klow blend contains (GHK-Cu + BPC-157 + TB-500 + KPV), why combinations are studied, and the analytical rigor blends require.
Research Explainer · August 3, 2026MOTS-c and AMPK/PGC-1α signaling, latest 2025–2026 research on muscle bioenergetics, glucose metabolism, and pancreatic islet health.
Research Explainer · August 3, 2026Semax (BDNF upregulation) and Selank (anxiolytic): Russian-developed peptides, preclinical mechanisms, and their July 2026 FDA advisory vote.
Research Explainer · August 3, 2026GHRH analog + ghrelin-mimetic: how they work, why they're studied together, synergistic GH and IGF-1 effects, and regulatory status.
Mechanism Deep-Dive · August 3, 2026Brain-derived neurotrophic factor and TrkB receptor signaling: why BDNF upregulation matters, age-related decline, and nootropic implications.
Regulatory · August 3, 2026An advisory vote is not an agency action. The rulemaking that still has to happen, the 12–24 month estimate, the criteria at 21 CFR 216.23 — and the second meeting due in February 2027, with GHK-Cu on the agenda.
Trial Readout · August 3, 2026A 112-week Lancet trial randomised participants to continue, halve or stop after the weight came off. Two thirds of the placebo arm needed rescue therapy; 8% of those who continued did.
Analysis & Purity · August 3, 2026FDA's briefing materials noted multiple forms — and sometimes multiple published amino acid sequences — under the same peptide name. What a COA settles, and what it honestly does not.
Regulatory · August 2, 2026Six recommended, one rejected — the vote counts for BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax and Emideltide, and why FDA's own scientists disagreed.
Research Comparison · August 2, 2026The TRIUMPH Phase 3 numbers, and the diminishing-returns pattern that shows up when you line the three agonist tiers side by side.
Mechanism Deep-Dive · August 2, 2026Dermal papilla signaling, the day-6 vs day-9 minoxidil comparison, and why the wound-healing evidence is far stronger than the hair evidence.
Research Comparison · August 2, 2026A signal encoded in mitochondrial DNA versus a synthetic tetrapeptide that binds cardiolipin — complementary mechanisms, not alternatives.
Research Explainer · August 2, 2026The PepT1-mediated, receptor-independent anti-inflammatory mechanism reported for KPV in colitis models, and its FDA compounding status.
Regulatory News · August 2, 2026FORZINITY became the first FDA-approved mitochondrial-disease drug in Sept. 2025. What the TAZPOWER trial showed, and what stays research-only.
Research Methodology · August 2, 2026Translational failure rates, physiology gaps, and how to read a preclinical peptide claim without overstating it.
Research Comparison · August 2, 2026Two unrelated peptides, two different mechanisms — VEGFR2 angiogenesis vs. actin-regulated cell migration — compared on the preclinical evidence.
Mechanism Deep-Dive · August 2, 2026The folate-cycle mechanism reported for MOTS-c, the "exercise mimetic" framing, and what the mouse-model data on glucose metabolism shows.
Regulatory · August 2, 2026The DQSA, the nomination process, the PCAC's four evaluation criteria, and the January 2025 rule change that now blocks compounding until full review clears.
Reference Guide · August 2, 2026The Merrifield method, Fmoc vs Boc chemistry, and why the coupling-deprotection cycle is the root cause of the impurities a COA reports.
Lab Technique · August 2, 2026Benzyl alcohol, multi-dose vs single-dose vials, and the 28-day open-vial window, per FDA-indexed prescribing information.
Research Explainer · August 1, 2026What preclinical research reports on GHK-Cu, collagen synthesis and skin regeneration — and what's not yet proven in humans. Research use only.
Regulatory · August 1, 2026The FDA's RUO/IUO framing explained: what it obligates sellers and buyers to do, and what it does not mean for legality or safety.
Lab Technique · July 30, 2026HPLC purity, mass spec identity, net peptide content, TFA salt, water content, LAL endotoxin — and why third-party labs matter.
Lab Technique · July 30, 2026Diluent choice, slow vial-wall injection, and the common handling mistakes that degrade a sample.
Mechanism Deep-Dive · July 30, 2026The receptor signaling cascade behind angiogenesis research — and why it's central to BPC-157 vascular studies.
Clinical Research News · July 27, 2026One peptide, three receptors - GIP, GLP-1 and glucagon. What the peer-reviewed Lancet and NEJM Phase 2 trials and the Phase 3 TRIUMPH topline actually report. Investigational compound; research use only.
Research Explainer · July 26, 2026Actin biology, an 80-study scoping review, the RGN-259 Phase III results, and the FDA compounding record - what the evidence does and does not establish. Research use only.
Research & Education · July 25, 2026A research-only guide to BPC-157 — what preclinical studies report on tissue repair and gut health, the latest 2026 research directions, and where the FDA now stands after its July 2026 advisory vote. Read more →
Regulatory · July 23, 2026The FDA's Pharmacy Compounding Advisory Committee is reviewing seven research peptides — including BPC-157, TB-500, KPV, MOTs-C, Semax and Epitalon — for the 503A bulk substances list on July 23–24, 2026. Here's what's on the agenda and what it means. Read more →
More updates coming soon.